Mammalian cells integrate mitogen and stress signalling before the end of G1 phase to determine whether or not they enter the cell cycle 1-4 . Before cells can replicate their DNA in S phase, they have to activate cyclin-dependent kinases (CDKs), induce an E2F transcription program and inactivate the anaphase-promoting complex (APC/C CDH1 , also known as the cyclosome), which is an E3 ubiquitin ligase that contains the co-activator CDH1 (also known as FZR, encoded by FZR1). It was recently shown that stress can return cells to quiescence after CDK2 activation and E2F induction but not after inactivation of APC/C CDH1 , which suggests that APC/C CDH1 inactivation is the point of no return for cell-cycle entry 3 . Rapid inactivation of APC/C CDH1 requires early mitotic inhibitor 1 (EMI1) 3,5 , but the molecular mechanism that controls this cell-cycle commitment step is unknown. Here we show using human cell models that cell-cycle commitment is mediated by an EMI1-APC/C CDH1 dual-negative feedback switch, in which EMI1 is both a substrate and an inhibitor of APC/C CDH1 . The inactivation switch triggers a transition between a state with low EMI1 levels and high APC/C CDH1 activity during G1 and a state with high EMI1 levels and low APC/C CDH1 activity during S and G2. Cell-based analysis, in vitro reconstitution and modelling data show that the underlying dual-negative feedback is bistable and represents a robust irreversible switch. Our study suggests that mammalian cells commit to the cell cycle by increasing CDK2 activity and EMI1 mRNA expression to trigger a one-way APC/ C CDH1 inactivation switch that is mediated by EMI1 transitioning from acting as a substrate of APC/C CDH1 to being an inhibitor of APC/C CDH1 . To gain insights into the molecular control of APC/C CDH1 inactivation, we used a live-cell reporter for APC/C CDH1 activity 3 and tested in non-transformed human MCF10A breast epithelial cells whether APC/ C CDH1 inactivation has the hysteresis characteristic that is required for an irreversible cell-cycle commitment decision. As outlined in Fig. 1a , bistable decisions in cell signalling require hysteresis, which means that only weak inhibition of the trigger activity should keep APC/C CDH1 'on' (solid line in Fig. 1a ) whereas strong inhibition of the same trigger activity should keep the inactivated APC/C CDH1 switch 'off ' (dashed line in Fig. 1a ) (Extended Data Fig. 1a-c) . When we titrated a CDK1/2 inhibitor during G1 phase while APC/C CDH1 was on, or during S or G2 phase while APC/C CDH1 was off, we found that the half-maximal effective concentration (EC 50 ) required to maintain APC/C CDH1 in the on state was 1.68 μM, whereas the EC 50 required to turn inactive APC/C CDH1 back to the on state was higher than 30 μM (Fig. 1b and Extended Data Fig. 1e) . Thus, cells stay in their respective on or off APC/C CDH1 state over a greater than 20-fold concentration window of the CDK1/2 inhibitor, demonstrating robust hysteresis. When we measured the fraction of cells that failed to turn APC/C CDH1 off as a function of APC/C CDH1 activity at the time of the drug spike (Extended Data  Fig. 1f, g ), we found that about 30% of maximal activity of APC/C CDH1 reflects a threshold of APC/C CDH1 activity at which APC/C CDH1 inactivation becomes irreversible. The CDK2-regulated trigger mechanism, marked hysteresis and threshold together suggest that APC/C CDH1 inactivation is a robust bistable switch.
C CDH1 inactivation switch that is mediated by EMI1 transitioning from acting as a substrate of APC/C CDH1 to being an inhibitor of APC/C CDH1 . To gain insights into the molecular control of APC/C CDH1 inactivation, we used a live-cell reporter for APC/C CDH1 activity 3 and tested in non-transformed human MCF10A breast epithelial cells whether APC/ C CDH1 inactivation has the hysteresis characteristic that is required for an irreversible cell-cycle commitment decision. As outlined in Fig. 1a , bistable decisions in cell signalling require hysteresis, which means that only weak inhibition of the trigger activity should keep APC/C CDH1 'on' (solid line in Fig. 1a ) whereas strong inhibition of the same trigger activity should keep the inactivated APC/C CDH1 switch 'off ' (dashed line in Fig. 1a ) (Extended Data Fig. 1a-c) . When we titrated a CDK1/2 inhibitor during G1 phase while APC/C CDH1 was on, or during S or G2 phase while APC/C CDH1 was off, we found that the half-maximal effective concentration (EC 50 ) required to maintain APC/C CDH1 in the on state was 1.68 μM, whereas the EC 50 required to turn inactive APC/C CDH1 back to the on state was higher than 30 μM ( Fig. 1b and Extended Data Fig. 1e ). Thus, cells stay in their respective on or off APC/C CDH1 state over a greater than 20-fold concentration window of the CDK1/2 inhibitor, demonstrating robust hysteresis. When we measured the fraction of cells that failed to turn APC/C CDH1 off as a function of APC/C CDH1 activity at the time of the drug spike (Extended Data Fig. 1f, g ), we found that about 30% of maximal activity of APC/C CDH1 reflects a threshold of APC/C CDH1 activity at which APC/C CDH1 inactivation becomes irreversible. The CDK2-regulated trigger mechanism, marked hysteresis and threshold together suggest that APC/C CDH1 inactivation is a robust bistable switch.
For a signalling system to generate a bistable switch, it requires-in addition to hysteresis-positive or dual-negative feedback 6 (Fig. 1a) . We first investigated known APC/C CDH1 substrates that may also negatively regulate APC/C CDH1 to generate dual-negative feedback. The cullin E3 ligases SCF SKP2 and SCF cyclin F have both previously been reported to degrade APC/C CDH1 components 7, 8 , and cyclin A2-CDK2 can mediate APC/C CDH1 inhibition by phosphorylating CDH1 9, 10 . Knockdown of cyclin A2 (encoded by CCNA2), SKP2 (encoded by SKP2), or cyclin F (encoded by CCNF) (Extended Data Fig. 2a-c) did not affect the inactivation kinetics of APC/C CDH1 in three cell types (HeLa, MCF10A and U2OS; , suggesting that these substrates may tune APC/C activity in other phases of the cell cycle but do not control the rapid APC/C CDH1 inactivation at the G1-S transition. By contrast, knockdown of the APC/C CDH1 inhibitor EMI1 (also known as FBXO5) 5, 11 , resulted in a decrease in the rate of APC/C CDH1 inactivation (Fig. 1c and Extended Data Figs. 2d, . Notably, hysteresis in APC/C CDH1 inactivation was completely lost when EMI1 was knocked down (Fig. 1d and Extended Data Figs. 1e, 3d) . Thus, EMI1 is responsible for the fast kinetics, bistability and hysteresis observed in APC/C CDH1 inactivation. We measured EMI1 protein levels during the cell cycle to determine whether EMI1 not only inhibits APC/C CDH1 , but also whether it may be part of a dual-negative feedback by being degraded by APC/C CDH1 in G1 (Extended Data Fig. 3e ). EMI1 protein levels were low in G1 phase when APC/C CDH1 is active and first started to accumulate about six hours after mitosis, coincident with the inactivation of APC/C CDH1 (Fig. 2a and Extended Data Fig. 4a, b) . Low EMI1 protein levels in G1 phase are a consequence of EMI1 degradation during G1, as shown by the fact that treatment with the proteasome inhibitor MG132 increased EMI1 levels (Extended Data Fig. 4c ). This degradation of EMI1 is unlikely to be mediated by polo-like kinase and the β-TRCP subunit of SCF complex (SCF β-TRCP ) 12 as these regulators of EMI1 degradation are active in pro-metaphase, and not in G1 phase 13 . Inhibition with the small molecule APC/C inhibitor proTAME 14 increased EMI1 levels as well as the level of the APC/C substrate cyclin A2 (Fig. 2b) , consistent with EMI1 being degraded in G1 by APC/C CDH1 . In a second strategy to test whether EMI1 is a substrate of APC/C CDH1 in G1, we used single-cell analysis of both EMI1 mRNA copy number and protein levels during G1 (Extended Data Fig. 4d ). We confirmed that the mRNAs of the known E2F targets EMI1, geminin (encoded by GMNN), E2F1 (encoded by E2F1) and cyclin E1 (encoded by CCNE1) all immediately start to increase after anaphase ( Fig. 2c and Extended Data Fig. 4e, f) , and that cyclin E1 protein levels closely follow CCNE1 mRNA levels ( Fig. 2d and Extended Data Fig. 5a ). By contrast, the increase of both geminin and EMI1 protein levels were delayed compared to their respective mRNAs (Fig. 2c, d and Extended Data Fig. 5b, c) . Both geminin-a well-characterized APC/C CDH1 substrate-and EMI1 protein levels started accumulating about 5-6 h after anaphase, which is precisely when APC/C CDH1 is inactivated and
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5-ethnyl-2′-deoxyuridine (EdU) starts to be incorporated at the start of S phase (single-cell analysis in Extended Data Fig. 5d , e). We also tested for a role of APC/C CDH1 in degrading EMI1 by knocking down CDH1 with short interfering RNA (siRNA), and found that both geminin and EMI1 protein levels accumulated much earlier in cells transfected with CDH1 siRNA as compared to control siRNA (Extended Data Fig. 5f, g ), further confirming that APC/C CDH1 is required for EMI1 degradation in G1.
To determine whether EMI1 is a direct substrate of APC/C CDH1 , we used recombinant EMI1 and immuno-purified APC/C CDH1 along with ubiquitin, E1, E2 enzymes (UBE2C and UBE2S) and ATP to test for EMI1 ubiquitination in vitro. APC/C CDH1 was markedly efficient at ubiquitinating recombinant EMI1 when relatively low concentrations of EMI1 (23 nM) were used in this assay, which provides evidence that EMI1 is a direct substrate for APC/C CDH1 (Fig. 2e) . A kinetic analysis of EMI1 ubiquitination revealed that EMI1 is a distributive substrate 15 , which means that EMI1 poly-ubiquitination requires multiple successive encounters of EMI1 with APC/C CDH1 (Extended Data Fig. 5h, i ). Using mutant ubiquitins that lack one or all lysines, we also found that EMI1 is primarily poly-ubiquitinated via K11 and K48 ubiquitin linkages, similar to other APC/C CDH1 substrates 16 (Extended Data Fig. 5j ). Having established that EMI1 is an APC/C CDH1 substrate that can be degraded by APC/C CDH1 in G1 phase, the questions arise of whether and how EMI1 can also be an inhibitor of APC/C CDH1 in S and G2 phases of the cell cycle. Although it is conceivable that this transition is regulated by post-transcriptional modifications on EMI1
17
, previous structural data have identified binding interactions between two domains of EMI1 and two different regions of APC/C CDH1 (refs 18,19 ) ( Fig. 3a and Extended Data Fig. 6a, b) , which suggests that EMI1 may switch from being a substrate to an inhibitor by using two separate binding sites on APC/C CDH1 . First, EMI1 binds to the substrate adaptor proteins CDH1 and APC10 through an RXXL (in which X denotes any amino acid) D-box motif, similar to typical APC/C CDH1 substrates. Second, EMI1 binds to APC1, APC2 and APC11 through its zinc-binding region and to APC2 via its C-terminal LRRL sequence, which blocks the binding of the E2 ubiquitin-conjugating enzymes. We tested mutants CDH1 inhibitor EMI1 is also an APC/C CDH1 substrate that is degraded during G1 and builds up at the G1-S transition. a, HeLa cells were synchronized with nocodazole (noc) and mitotic shakeoff. Image is representative of three independent experiments. b, HeLa cells were treated as in a, but 1.5 h after release cells were treated with either DMSO or 30 μM proTAME, a small-molecule APC/C inhibitor (APCi). Lysates were collected 4 h after release. Image is representative of two independent experiments. c, d, Live-cell imaging was combined with fixed-cell analysis to measure mRNA (c) or protein and 5-ethynyl-2′-deoxyuridine (EdU) (d) levels over time since mitosis. Median levels from 1-h bins were plotted. n = 2 independent experiments. e, In vitro ubiquitination assay using APC/C from cells in G1 phase and recombinant EMI1 (amino acids 299-447). E2C/S, E2 enzymes UBE2C and UBE2S; IP, immunoprecipitated; rEMI1, recombinant EMI1; Ub n , a variable number (n) of ubiquitins linked in a chain. Image is representative of two independent experiments.
Letter reSeArCH of EMI1 that were deficient in each of the two binding interactions and used MCF10A cells in which the addition of a CDK4/6 inhibitor can block the APC/C CDH1 inactivation that normally occurs in most cells within 5 h of mitosis ( Fig. 3b and Extended Data Fig. 6c-e) . We first confirmed that overexpression of wild-type EMI1 potently inhibited APC/C CDH1 immediately after mitosis in the presence of the CDK4/6 inhibitor, which shows that EMI1 can turn off APC/C CDH1 on its own ( Fig. 3c and Extended Data Fig. 6f, g ). We then made a point mutation (EMI1(C401S); Extended Data Fig. 6d ) that was previously shown to disrupt the zinc-binding region domain of EMI1 and thereby prevent EMI1(C401S) from inhibiting the binding of E2 enzymes to APC/C CDH1 (ref.
11
). Expressed EMI1(C401S) markedly failed to inactivate APC/ C CDH1 in this system ( Fig. 3d and Extended Data Fig. 6f, h ) and was instead degraded in the absence of CDK4/6 inhibitor in parallel with other APC/C CDH1 substrates (Extended Data Fig. 6j, k) , which suggests that an interaction of EMI1 with the substrate region alone can lead to EMI1 ubiquitination and degradation without inhibiting APC/C CDH1 .
To determine whether the interaction of EMI1 with only the region to which the E2 enzymes bind is sufficient to inhibit APC/C CDH1 , we mutated the APC/C-degron motif in EMI1 to prevent its interaction with this substrate docking site (EMI1(AXXA); Extended Data Fig. 6d ). Expression of the EMI1(AXXA) mutant rescued the effects of CDK4/6 inhibition to control levels, and almost as well as did overexpressing wild-type EMI1 (Fig. 3b , c, e and Extended Data Fig. 6l ), which suggests that EMI1 binding to the E2 enzyme interaction region can be sufficient to inhibit APC/C CDH1 without requiring the interaction with the substrate region. Independent interactions of EMI1 with the substrate and inhibitory regions of APC/C CDH1 are further supported by the previous finding that EMI1 and the APC/C CDH1 substrate geminin can both bind to APC/C CDH1 at the same time as part of a ternary complex
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. Together with previous structural and biochemical results [18] [19] [20] , our data suggest that EMI1 functions independently as a substrate of APC/C CDH1 by binding to the substrate region and that it also acts as an inhibitor of APC/C CDH1 by either binding to the region that interacts with E2 enzymes or at the same time to both regions ( Fig. 3f) .
We developed a computational model to determine how an inhibitor of an E3 ligase that is also a substrate may generate a robust bistable switch (Extended Data Fig. 7a ). In the model, EMI1 reversibly binds to a low-affinity substrate-binding site of APC/C CDH1 at which it can be mono-and poly-ubiquitinated in a non-processive manner. EMI1 also reversibly binds with higher affinity to the inhibitory site(s) to suppress poly-ubiquitination and subsequent degradation of substrates by inhibiting binding to E2 enzymes 20 ( Fig. 3f) . At low concentrations of EMI1, EMI1 and other substrates can be degraded as EMI1 levels are initially lower than APC/C CDH1 levels and the fraction of inhibited APC/C CDH1 is therefore insufficient to block overall APC/C CDH1 activity. As EMI1 levels increase, the increasing occupancy of the inhibitory site of APC/C CDH1 suppresses poly-ubiquitination of unbound EMI1 and other substrates. This system has the cooperativity required for a robust switch mechanism ( Fig. 1a and Extended Data Fig. 3e ), because multiple ubiquitins have to be added to enable substrate degradation 21, 22 . The model includes a term for E2F-regulated synthesis of EMI1 mRNA after mitosis and also for a slow increase in CDK2 activity that partially inhibits APC/C CDH1 to initiate the switch mechanism, which cells trigger at a threshold of approximately 70% APC/C CDH1 inhibition (Extended Data Fig. 1f, g ).
A steady-state analysis of the model at constant EMI1 mRNA levels and CDK2 activity (Fig. 3g) shows the relationship between EMI1 levels and synthesis rate represents a bistable system with an APC/C CDH1 -on, low-EMI1 state (Fig. 3g , left panel), and an APC/C CDH1 -off, high-EMI1 state (Fig. 3g , middle panel). Once the system reaches the off state, APC/C CDH1 activity becomes independent of CDK2 activity (Fig. 3g , right panel), a prediction that closely matches the hysteresis that we observed experimentally (Fig. 1b and Extended Data Fig. 7b) .
A second key prediction of the model is that at concentrations of EMI1 below that of APC/C CDH1 , EMI1 should be efficiently ubiquitinated by APC/C CDH1 , but at concentrations higher than that of APC/C CDH1 , EMI1 should be poorly ubiquitinated. To test this prediction, we conducted in vitro ubiquitination assays with both low and high concentrations of EMI1. EMI1 was efficiently poly-ubiquitinated when we added 23 nM of recombinant EMI1 to an in vitro ubiquitination assay, but poly-ubiquitination of EMI1 was completely inhibited at 2.9 μM EMI1, which is consistent with robust APC/C CDH1 inhibition (Fig. 4a ). This is also true for other substrates; geminin was poly-ubiquitinated by APC/C CDH1 in the presence of 23 nM EMI1 but the poly-ubiquitination of geminin by APC/C CDH1 was completely inhibited when we added 2.9 μM EMI1 (Extended Data Fig. 8a ). EMI1 added at the higher concentration (2.9 μM) could still be mono-ubiquitinated by APC/C CDH1 , as was geminin ( Fig. 4b and Extended Data Fig. 8b ), which is consistent with a previous observation that EMI1 may inhibit ubiquitin chain elongation primarily by interfering with UBE2S binding 18, 20 . We also observed the same concentration-dependent ubiquitination of EMI1 when we used the CDC20 co-activator subunit of APC/C (APC/C CDC20 ) in the in vitro ubiquitination assays, indicating that EMI1 is also a substrate of APC/C CDC20 (Extended Data Fig. 8c ). Using densitometry of the ubiquitinated bands, we observed a nonlinear transition Letter reSeArCH between EMI1 being a substrate with five or more ubiquitins attached and an inhibitor (Extended Data Fig. 8d ). Taken together, our data support a model in which EMI1 is a substrate of APC/C CDH1 when EMI1 is present at low concentrations, and an inhibitor of APC/C CDH1 when it exceeds the concentration of APC/C CDH1 (Fig. 4c) . Our model also predicted that cells should trigger bistable APC/C CDH1 inactivation even when EMI1 mRNA increases without an increase in CDK2 activity (Fig. 4d , e and Extended Data Fig. 8e ). We found that HeLa and U2OS cells treated with siRNA against both CCNE1 and CCNE2 (encoding cyclin E1 and cyclin E2, respectively) (see Extended Data Fig. 2e ) rapidly inactivate APC/C CDH1 after a delay, indicating that APC/C CDH1 can be inactivated independently of CDK2 23 activity if EMI1 synthesis is constitutively active and EMI1 mRNA reaches high enough levels ( Fig. 4f and Extended Data Fig. 9a-f) . Thus, cells can bypass the requirement for G1 cyclin E-CDK2 activity by upregulating EMI1 mRNA levels to inactivate APC/C CDH1 , providing a redundant mechanism to start the cell cycle ( Fig. 4g and Extended Data Fig. 10a-d) . This alternative path to S phase is probably important in cancer cells that often have mis-regulated E2F, retinoblastoma (Rb) protein or upstream regulators that constitutively activate E2F 24 (Extended Data Fig. 10d) . Notably, we observed that knockdown of EMI1 in U2OS cells completely prevented APC/C CDH1 inactivation (Extended Data Figs. 3c, 10c) , suggesting that cyclin E-CDK2 activity alone does not reach sufficiently high levels in U2OS cells to inactivate APC/C CDH1 independently of EMI1. Although CDK2 activity alone is capable of inactivating APC/C CDH1 in some-but not all-cell lines, the dual-negative feedback loop between EMI1 and APC/C CDH1 is required for rapid and irreversible APC/C CDH1 in every cell line tested, indicating it is likely to be a general feature of cell-cycle entry control.
Our results provide a mechanistic model for mammalian cell-cycle commitment. We previously demonstrated that the activation of Rb-E2F and cyclin E-CDK2-which is thought to underlie the mammalian restriction point-remains reversible when cells are exposed to stress, until APC/C CDH1 is inactivated several hours later 3 . Thus, cells pass through two sequential steps in cell-cycle entry: Rb inactivation followed by APC/C CDH1 inactivation. Only after this second step can cells no longer return to quiescence. Here we have shown that EMI1 mRNA and cyclin E-CDK2 are synergistic triggers of a bistable switch mechanism that is driven by dual-negative feedback between EMI1 and APC/C CDH1 . Figure 4h positions this EMI1-APC/C CDH1 inactivation switch within the overall cell cycle, showing that cells turn on APC/C CDH1 when they exit mitosis and keep APC/C CDH1 on during quiescence and G1, before the EMI1-APC/C CDH1 inactivation switch is triggered at the G1-S transition, at which time cells irreversibly commit to the cell cycle.
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Any Methods, including any statements of data availability and Nature Research reporting summaries, along with any additional references and Source Data files, are available in the online version of the paper at https://doi.org/10.1038/s41586-018-0199-7. CDH1 inactivation switch and cell-cycle commitment. a, In vitro ubiquitination assay using immuno-purified APC/C CDH1 and recombinant EMI1. After the in vitro reaction, equal amounts of EMI1 were loaded onto the gel for western blotting. Image representative of n = 2 independent experiments. b, As in a, but using a range of concentrations of recombinant EMI1. Image representative of n = 2 independent experiments. c, Schematic showing that at low concentrations of EMI1, EMI1 can be poly-ubiquitinated, but at high concentrations of EMI1, EMI1 inhibits E2 activity and chain elongation. d, Schematic of a bistable switch involving cyclin E1-and cyclin E2-CDK2 and a dual-negative feedback loop between APC/ C CDH1 and EMI1. e, Simulated changes in APC/C CDH1 activity in G1 and S phases. f, HeLa cells treated with the indicated siRNA. APC/C and CDK2 activity were measured in the same cells, and traces were aligned to mitosis. Data are median activity trace ± s.e.m. g, Phase-plane diagram of median CDK2 and APC/C activity measured simultaneously in the same HeLa cells. n = 270 cells per condition. h, APC/C CDH1 inactivation at the G1-S transition is a one-way switch, triggered by CDK2 activity and made irreversible by a dual-negative feedback mechanism with EMI1.
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MEthodS
No statistical methods were used to predetermine sample size. The experiments were not randomized and investigators were not blinded to allocation during experiments and outcome assessment. Cell culture. MCF10A cells were obtained from ATCC (CRL-10317) and were cultured in phenol-red-free DMEM/F12 (Invitrogen) supplemented with 5% horse serum, 20,000 pg/ml EGF, 10 μg/ml insulin, 0.5 μg/ml hydrocortisone, 100 ng/ml cholera toxin, 50 U/ml penicillin and 50 μg/ml streptomycin. HeLa (ATCC, CCL-2) and U2OS cells were cultured in DMEM (Invitrogen) plus 10% fetal bovine serum (FBS) and penicillin-streptomycin-glutamine (PSG). HeLa and U2OS cells were used because they both have constitutively active E2F-mediated transcription, which is necessary to test our hypothesis that EMI1 can inactivate APC/C independently of CDK2 activity. All cell lines were tested for mycoplasma contamination. Where indicated, cells were treated with the small molecule inhibitors CDK1/2i III (3 μM, EMD Biosciences #217714), CDK4/6i (1 μM, PD-0332991), MG132 (10 μM) and proTAME (30 μM, Boston Biochem). Synchronization. HeLa cells were treated with 2 mM thymidine for 24 h, washed and allowed to grow in regular growth medium for 3 h. Cells were then treated with 100 ng/ml nocodazole for 9-12 h. Cells synchronized in mitosis were then isolated by mitotic shake-off and re-plated after washing with regular growth medium. Constructs. CSII-pEF-H2B-mTurquoise and CSII-pEF-DHB(amino acids 994-1087)-mVenus have previously been described 23 . CSII-pEF-geminin(amino acids 1-110)-mCherry has previously been described 3 . EMI1 fused to mCitrine was cloned into the CSII-pEF lentiviral vector. The EMI1 C355S mutation was made in the CSII-pEF-EMI1-mCitrine construct using the Gibson assembly method with the mutation encoded in the primers. Coding sequences for human His-EMI1(amino acids 299-447) was cloned into pET28 for purification from Escherichia coli. Transduced cells were sorted on a Becton Dickinson Influx to obtain pure populations expressing the desired fluorescent reporters. Time-lapse microscopy and image analysis. Cells were plated at least 24 h before imaging in full growth medium in a 96-well dish (Costar #3904) such that the density would remain sub-confluent until the end of the imaging period. Timelapse imaging was performed in 290 μl full growth medium. Images were taken in CFP, YFP and RFP channels every 12 min on an IXMicro microscope (Molecular Devices) with a 10× objective and 0.3 NA. Total light exposure time was kept under 600 ms for each time point. Cells were imaged in a humidified, 37 °C chamber in 5% CO 2 . Image processing, cell tracking and APC/C activity quantification was done using custom MATLAB scripts that have previously been described 3 .
Immunofluorescence. Cells were fixed in 4% paraformaldehyde, washed three times in PBS, permeabilized with 0.2% triton and stained overnight at 4 °C with anti-SKP2 (Cell Signaling Technology, #4358), anti-Geminin (Sigma-Aldrich, HPA049977), anti-EMI1 (Invitrogen, 37-6600), anti-Cyclin E1 (Santa Cruz Biotechnology, sc-247) or anti-Cyclin F (Santa Cruz Biotechnology, sc-952). Cells stained with anti-Cyclin E1 were treated with ice-cold 100% methanol for 5 min after initial fixing with 4% paraformaldehyde. Primary antibodies were visualized using a secondary antibody conjugated to Alexa Fluor-647 and imaged with a Far Red filter. Where indicated, cells were treated with 10 μM EdU for 15 min unless otherwise specified, and fixed and processed according to manufacturer's instructions (Invitrogen, #C10356). RNA fluorescence in situ hybridization. RNA in situ hybridization was carried out using the Affymetrix Quantigene ViewRNA ISH cell assay kit and mRNA quantification was carried out using custom MATLAB scripts as described previously 3 . Probes were custom designed (Affymetrix) to target EMI1, geminin, cyclin E1 or E2F1. After fluorescence in situ hybridization (FISH) staining, cells were blocked in PBS containing 10% FBS, 1% BSA, 0.1% TX-100 and 0.01% NaN 3 for 1 h at room temperature, and then stained overnight with antibodies for immunofluorescence. Live-cell imaging combined with fixed-cell analysis. To generate time-course measurements of mRNA, protein and EdU levels, we combined live-cell imaging and fixed-cell analysis. HeLa cells were used to simplify the analysis, because HeLa cells do not enter quiescence after mitosis. We tracked unsynchronized cells using H2B-mTurquoise and imaged them for approximately 20 h. At the end of the live-cell imaging, cells were grown in 10 μM EdU for 15 minutes. The time since the previous anaphase before fixing was recorded for each individual cell. The cells were then stained for mRNA using RNA FISH (see 'RNA fluorescence in situ hybridization'), protein using immunofluorescence, and for EdU, and imaged on the same microscope used for the live-cell imaging. Custom MATLAB scripts were used to re-align the fixed-cell image with the last frame of the time-lapse imaging and then quantify the mRNA, protein and EdU levels for each cell. Thus, for each cell the time since anaphase, as well as mRNA, protein and EdU levels was recorded. Cells were binned in 1-h intervals and the median value of each bin was calculated and plotted on an axis. Lines were normalized by the mRNA values at the onset of S phase (as measured by EdU incorporation), which was 6 h after anaphase, or to the maximum protein levels. siRNA transfection. MCF10A and HeLa cells were transfected using Dharmafect 1 (Thermo Scientific) according to the manufacturer's instructions and U2OS cells were transfected with Lipofecatime RNAiMAX (Thermo Fisher Sceintific) according to the manufacturer's instructions. The following siRNAs were used: control siRNA (nontargeting #2, Dharmacon), siGenome pooled set of four siRNAs for CCNA2, siGenome pooled set of four siRNAs for SKP2, siGenome pooled set of four siRNAs for CCNF, siGenome pooled set of four for EMI1, siGenome pooled set of four for FZR1 (CDH1), and siGenome pooled set of eight for CCNE1 and CCNE2 (Dharmacon) at final concentrations of 20 nM unless noted. Six hours post-transfection, cells were washed with full growth medium and then imaging was immediately started. Cells were only considered if they went through one mitosis within the imaging period. This method works efficiently, because all the genes targeted in this study are known to be degraded during or before the onset of mitosis. Thus, the siRNA would prevent subsequent accumulation in the next cell cycle. In vitro ubiquitination Assay. Human APC/C was purified from extracts of prometaphase or G1 HeLa cells 16 . For G1 extracts, prometaphase cells were washed twice in PBS and released from nocodazole-arrest for 2 h in drug-free medium. His-EMI1(amino acids 299-447) was purified as previously described 16, 25 . We used the C-terminal domain of EMI1, which contains all of the APC/C-interacting domains (amino acids 299-447) and is commonly used for in vitro ubiquitination assays involving APC/C 18, 20 . In an 8-μl reaction volume, 0.5 μl of 10 μM E1 (625 nM final), 1 μl of 10 μM UBE2C (1.25 μM final), 1 μl of 10 μM UBE2S (1.25 μM final), 1 μl of 10 mg/ml ubiquitin (1.25 mg/ml final), 1 μl of 8 × ubiquitylation assay buffer (250 mM Tris 7.5, 500 mM NaCl and 100 mM MgCl 2 ), 1 μl of 100 mM DTT, 1.5 μl of energy mix (150 mM creatine phosphate, 20 mM ATP, 20 mM MgCl 2 , 2 mM EGTA, pH to 7.5 with KOH) and 1 μl of recombinant human EMI1 or geminin (ab86447, Abcam) was mixed with 5 μl of APC/C resin. Reactions were carried out at 30 °C for 1 h unless otherwise indicated and shaking at 1,000 r.p.m. Reactions were stopped by the addition of SDS sample loading buffer, resolved on a 12% SDS-acrylamide gel. For experiments comparing in vitro reactions using different concentrations of EMI1 on the same gel (Fig. 4a, b and Extended Data Fig. 8a, c) , equal amounts of EMI1 were loaded onto the gel to enable direct comparisons of band intensity using a single exposure. Immunoblotting. Cells were plated in equal number on 6-cm dishes. At the time of collection, cells were washed in ice-cold PBS. Protein extracts were produced by lysing cells directly in boiling 1× sample buffer and resolved by 4-20% gradient SDS-PAGE. Samples were subjected to immunoblotting with EMI1 antibodies (Fig. 2a, b and Extended Data Fig. 4c: 3D2D6 , Invitrogen or Figs. 2e, 4a, b and Extended Data Figs. 5h, j, , Zymed) at 1:1,000, cyclin A2 antibodies (sc-751, Santa Cruz Biotechnology) at 1:500, geminin antibodies (FL-209, Santa Cruz Biotechnology) and GAPDH antibodies (D16H11, Cell Signaling Technology) at 1:1,000. Immunoreactive species were visualized by chemiluminescent detection of horseradish peroxidase-conjugated secondary antibodies (7074 or 7076, Cell Signaling Technology). EMI1-APC/C modelling. Model calculation of the dual EMI1-APC/C CDH1 substrate and inhibitor switch were performed using a MATLAB program using the ODE45 solver for ordinary differential equations. The model calculates changes of the concentrations of non-ubiquitinated EMI1 and of EMI1 species with 1-5 ubiquitins conjugated. The model uses the following parameters and assumptions. First, because at least four ubiquitins have to be conjugated to a substrate for its effective degradation
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, and because substrates with five or more ubiquitins are more effectively degraded, we made a simplifying assumption that all EMI1 species that have more than five conjugated ubiquitins are degraded in cells. We did not distinguish possible rate variations if more than one mono-ubiquitin might be added or if different chains might be elongated in EMI1. Second, we made the simplifying assumption that only unbound EMI1 is ubiquitinated and that ubiquitinated EMI1 does not bind to the inhibitory site. This leads to a slower mono-ubiquitination of EMI1 26 because most EMI1 is bound to APC/C CDH1 in G1. Third, inhibition of APC/C CDH1 by EMI1 is modelled by using the concentration of APC/C CDH1 without bound inhibitory EMI1 as APC/C CDH1 activity. Total APC/C CDH1 concentration was assumed to be 500 nM, the affinity of the EMI1-APC/C CDH1 inhibitory binding interaction was assumed to be 5 nM and the maximal synthesis of EMI1 from EMI1 mRNA was assumed to be 10 nM/min. This rate increases with a time constant of 500 min from 0 nM/min. Fourth, based on our in vitro results, we included in our model the assumption that ubiquitination of EMI1 is not processive, assuming faster binding and dissociation of EMI1 substrates (γ+ and γ− terms) compared to ubiquitin chain elongation of the bound EMI1 substrate. When simulated, this model recapitulates the fast inactivation of APC/C that we observed in cells (<1 h) when we selected for the model an overall rate at which the chain of ubiquitinated EMI1 is elongated of 3.7/min (binding plus elongation) and a rate at which individual ubiquitins are removed from poly-ubiquitinated EMI1 (the β term) of 2/min. The ratio of these two parameters is the most relevant factor for the model. Finally, we modelled inhibition by CDK2 as a normalized factor (r) that is 1 at the start and inactivates APC/C CDH1 using a time constant of
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Extended Data Fig. 1 | Single-cell APC/C CDH1 data used to determine hysteresis curves. a, Experimental setup for Fig. 1b Histograms to the right of each panel give APC/C activity at the last frame of the movie for each cell. Pie chart insets give the percentage of cells with APC/C still active at the end of the movie. c, Scatter plot of CDK2 activity at the time of drug spike, plotted against the CDK2 activity from the same cell 1 h later. Cells at all phases of the cell cycle were included. d, Top, representative APC/C activity traces for MCF10A cells in G1 phase at time of the indicated treatment. Bottom, representative APC/C activity traces for MCF10A cells in S/G2 phase at time of the indicated treatment. Traces were coloured red if APC/C CDH1 was inactive and traces were coloured black if APC/C CDH1 was still active, at 5 h after addition of the drug. Pie charts show the percentage of cells with APC/C CDH1 still active, used to make the dose-response curve in Fig. 1b . e, Table of the EC 50 for the doseresponse curves in Fig. 1b, d ± s.e.m. n = 3 independent experiments. Doses above 30 μM CDK1/2 inhibitor killed the cells, making it impossible to calculate an EC 50 above 30 μM. f, MCF10A cells were treated with 10 μM CDK1/2 inhibitor and binned by their APC/C CDH1 activity at the time of drug addition. The percentage of cells in each bin with APC/C CDH1 activity on at 2.5 h after drug addition was calculated. Data were analysed by nonlinear regression (sigmoidal dose-response, variable slope). Error bars are s.d. from two independent experiments. g, Scatter plot of APC/C activity at the time of drug spike, plotted against the APC/C activity from the same cell 2.5 h later. Vertical dashed line represents the 70% inactive threshold. Horizontal line indicates the point at which APC/C activity is below 0.1, and is considered to be off. Fig. 2 | siRNA validation experiments. a-e, HeLa (a, b, e) or U2OS (c, d) cells were treated with the indicated siRNA for 24 h before fixation and immunostaining. Scale bars, 20 μm. Single-cell quantification of immunofluorescence data was used to generate the histograms. In a, n = 7,152 cells for siControl and n = 4,051 cells for siCCNA2.
Extended Data
In b, n = 7,772 cells for siControl and n = 3,916 cells for siSKP2. In c, n = 7,003 cells for siControl and n = 8,589 cells for siCCNF. In d, n = 9,393 cells for siControl and n = 7,871 cells for siEMI1. e, n = 64,574 cells for siControl and n = 53,338 cells for siCCNE1 and siCCNE2. Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
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Experimental design 1. Sample size
Describe how sample size was determined. Sample sizes were chosen empirically based on the observed effects and the number of single-cells tracked and listed in the figure legends. When available, at least 100 single cells were used per condition.
Data exclusions
Describe any data exclusions. For Cell cycle analysis, data from single cells were excluded if they were not in the designated cell cycle phase at the time of treatment. (e.g. Cells not arrested at Mitosis following thymadine/nocodazole block were excluded)
Replication
Describe whether the experimental findings were reliably reproduced.
The experimental findings were reliably reproduced using biological replicates and multiple cell lines.
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
No randomization was used as most quantifications were done using automatic image analysis in Matlab.
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Blinding was not relevant to our study, as all data quantification was performed with the same automated analysis computer code.
Note: all studies involving animals and/or human research participants must disclose whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.) A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided (note: only common tests should be described solely by name; more complex techniques should be described in the Methods section)
A description of any assumptions or corrections, such as an adjustment for multiple comparisons
The test results (e.g. P values) given as exact values whenever possible and with confidence intervals noted A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars
See the web collection on statistics for biologists for further resources and guidance.
